Artemis Medicare Services Limited

rs,

Kurla Complex, Bandra (E), Mumbai – 400 051 The Secretary, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 NSE Code: ARTEMISMED Scrip Code: 542919 Sub: Earnings Presenta

67%

and FY2025 Artemis Hospitals : At a Glance Established in July 2007 by promoters of Apollo Tyres (67% ownership), Artemis Hospital is one of the leading healthcare service providers in Delhi NCR 800+

rs 40

t centres operating cardiac care centres across India 500+ 500+ Full time Doctors Full time Doctors 40+ Specialities 12 Centres of Excellence 2 Consolidated Financial Highlights – Q4 FY25 Key Fina

6.5%

Excellence 2 Consolidated Financial Highlights – Q4 FY25 Key Financials (INR Mn) Gross Revenue 6.5% Net Revenue 6.6% EBITDA 31.9% 7.0% 2,357 2,521 9,222 9,819 6.5% 2,252 2,399 8,78

6.6%

olidated Financial Highlights – Q4 FY25 Key Financials (INR Mn) Gross Revenue 6.5% Net Revenue 6.6% EBITDA 31.9% 7.0% 2,357 2,521 9,222 9,819 6.5% 2,252 2,399 8,786 9,369 21.1%

31.9%

cial Highlights – Q4 FY25 Key Financials (INR Mn) Gross Revenue 6.5% Net Revenue 6.6% EBITDA 31.9% 7.0% 2,357 2,521 9,222 9,819 6.5% 2,252 2,399 8,786 9,369 21.1% 399 482 Q4

7.0%

ghlights – Q4 FY25 Key Financials (INR Mn) Gross Revenue 6.5% Net Revenue 6.6% EBITDA 31.9% 7.0% 2,357 2,521 9,222 9,819 6.5% 2,252 2,399 8,786 9,369 21.1% 399 482 Q4 FY24

21.1%

e 6.6% EBITDA 31.9% 7.0% 2,357 2,521 9,222 9,819 6.5% 2,252 2,399 8,786 9,369 21.1% 399 482 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 Margin:

17.7%

399 482 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 Margin: 17.7% 20.1% 1,401 1,848 FY24 15.9% FY25 19.7% Onkar Kanwar Chairman “Artemis concluded FY25 o

20.1%

482 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 Margin: 17.7% 20.1% 1,401 1,848 FY24 15.9% FY25 19.7% Onkar Kanwar Chairman “Artemis concluded FY25 on a str

15.9%

FY25 Q4 FY24 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 Margin: 17.7% 20.1% 1,401 1,848 FY24 15.9% FY25 19.7% Onkar Kanwar Chairman “Artemis concluded FY25 on a strong and positive trajectory,

19.7%

4 Q4 FY25 FY24 FY25 Q4 FY24 Q4 FY25 Margin: 17.7% 20.1% 1,401 1,848 FY24 15.9% FY25 19.7% Onkar Kanwar Chairman “Artemis concluded FY25 on a strong and positive trajectory, delivering co

“17.7% 20.1% 1,401 1,848 FY24 15.9% FY25 19.7% Onkar Kanwar Chairman “Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year.”

“During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base.”

“The strong growth in financial metrics has been driven by: • Leveraging economies of scale to improve operational efficiency through better allocation of fixed costs 1,036 15.0% FY23 1,459 464 481 • Plugging revenue leakages 400 18.0% 21.3% 19.2% 21.4% and running cost optimisation programs 21.4% • Supply chain and energy efficiency optimisations FY24 FY25 Q4 FY24 Q3 FY25 Q4 FY25”

“Operational Census Beds (Nos.) Occupancy Rate (%) ARPOB (INR) 456 511 522 78,800 80,200 82,800 66.9% 60.4% 60.8% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Patient Volumes (Nos.) Surgeries Performed (Nos.) ALOS (Days) 93,149 91,673 93,443 3,276 3,215 3,340 3.8 3.7 3.6 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 14 FY25 Operational Performance - Artemis Gurgaon Avg.”

Note

5

Margin

1

Margin

17.7% 20.1% 1,401 1,848 FY24 15.9% FY25 19.7% Onkar Kanwar Chairman “Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base. To fuel our next growth phase, we raised Rs 330 Crores from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 3 Accreditations and Centres of Excellence Accreditations Centres of Excellence National Accreditation Board for Hospitals & Healthcare Providers Artemis Organ Transplant Centre Artemis Women and Child Centre National Accreditation Board for Hospitals & Healthcare Providers - Blood Bank / Blood Centre National Accreditation Board for Hospitals & Healthcare Providers Certified Nursing Services Artemis Minimally Invasive & Bariatric Surgery Artemis Emergency & Trauma Centre Artemis Heart Centre Artemis Cancer Centre Intertek ISO 27001 Certificate First hospital in Gurugram to receive accreditation by Joint Commission International (JCI), USA The Laboratory services accredited by NABL based on ISO 15189:2012 for a specified scope of tests National Accreditation Board for Hospitals & Healthcare Providers – Ethics Committee Artemis Gastrosciences Centres Artemis Cosmetology & Plastic Surgery Centre Artemis

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 8 Artemis Hospital Gurgaon Q4 FY25 Revenue Segmentation by Speciality Q4 FY25 Revenue Segmentation by Payer 18% 20% 19% 32% 17% 18% 3% 3% 3% 3% 3% 3% 5% 8% 14% 31% Oncology Cardiology Nephrology Liver Transplant Neuro Internal Medicine Gastroentrology Obs & Gynae Orthopaedics General surgery Pulmonology Other Specialities International Patients Domestic Cash Patients Insured Patients Government Schemes 9 Artemis Hospital Gurgaon FY25 Revenue Segmentation by Speciality FY25 Revenue Segmentation by Payer 17% 20% 19% 29% 16% 19% 2% 3% 3% 3% 3% 4% 6% 9% 14% 33% Oncology Cardiology Nephrology Liver Transplant Neuro Internal Medicine Gastroentrology Obs & Gynae Orthopaedics General surgery Pulmonology Other Specialities International Patients Domestic Cash Patients Insured Patients Government Schemes 10 Artemis’ Ventures Overview Artemis Lite • Friendly neighborhood multi speciality hospitals, designed to fi

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 1,848 19.7% FY25 Quarterly Performance Trend 399 463 482 17.7% 19.9% 20.1% Q4 FY24 Q3 FY25 Q4 FY25 17 Q4 and FY25 Financial Performance (Consolidated) Particulars (INR Mn) Q4 FY25 Q4 FY24 Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA Margin Depreciation and amortisation expenses EBIT EBIT Margin Finance Cost PBT Total tax PAT PAT Margin

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 2,521 2,399 123 2,522 1,459 391 189 482 20.1% 117 365 15.2% 78 287 57 229 9.6% 2,357 2,252 19 2,271 1,341 361 171 399 17.7% 110 288 12.8% 86 202 59 143 6.4% YoY% 7.0% 6.5% 11.1% 8.8% 8.6% 10.7% 21.1% 6.4% 26.7% -8.7% 41.6% -3.2% 60.3% Q3 FY25 QoQ% 2,431 2,324 88 2,412 1,404 375 170 463 19.9% 115 348 15.0% 80 268 62 206 8.9% 3.7% 3.2% 4.6% 3.9% 4.5% 11.4% 4.3% 2.6% 4.8% -2.1% 6.9% -7.6% 11.3% FY25 9,819 9,369 330 9,699 5,652 1,484 715 1,848 19.7% 452 1,396 14.9% 319 1,077 255 822 8.8% FY24 9,222 8,786 74 8,859 5,403 1,389 666 1,401 15.9% 403 997 11.4% 313 685 193 491 5.6% YoY% 6.5% 6.6% 9.5% 4.6% 6.8% 7.4% 31.9% 12.0% 40.0% 2.1% 57.3% 32.0% 67.2% 18 Q4 and FY25 Financial Performance (Standalone) Particulars (INR Mn) Q4 FY25 Q4 FY24 Gross Revenue Net Revenue from Operations Other Income Total Income Operative Expenses Employee Benefit Expenses Other expenses EBITDA EBITDA Margin Depreciation and amortisa

Note

1. 2. EBITDA Includes Other Income Margins calculated on Net Revenue from Operations 2,466 2,348 122 2,470 1,430 380 183 478 20.3% 112 365 15.6% 75 290 58 232 9.9% 2,272 2,169 19 2,187 1,284 348 176 380 17.5% 105 275 12.7% 81 194 55 139 6.4% YoY% 8.5% 8.3% 12.9% 11.4% 9.3% 3.9% 25.8% 7.5% 32.7% -6.8% 49.1% 4.9% 66.6% Q3 FY25 QoQ% 2,375 2,269 88 2,357 1,373 363 164 456 20.1% 109 347 15.3% 77 270 63 208 9.2% 3.8% 3.5% 4.8% 4.1% 4.5% 11.5% 4.7% 2.8% 5.3% -1.6% 7.2% -7.5% 11.7% FY25 9,574 9,133 329 9,462 5,516 1,437 681 1,828 20.0% 430 1,397 15.3% 305 1,093 258 835 9.1% FY24 8,875 8,452 73 8,525 5,201 1,336 631 1,357 16.1% 380 976 11.6% 296 680 189 491 5.8% YoY% 7.9% 8.0% 11.0% 6.1% 7.6% 7.9% 34.7% 13.1% 43.1% 3.0% 60.6% 36.5% 69.8% 19 Balance Sheet Overview Standalone Consolidated Particulars (INR Mn) FY25 FY24 Particulars (INR Mn) FY25 FY24 Total Shareholders Funds 8,418 4,516 Total Shareholders Funds Total Loans Other Long Term Liabilities / Provisions Total Sources of Funds Net Fixed A